Future follow-up studies are necessary to identify whether the elevated syndecan-1 levels, as defined by our study, can predict treatment failure in controlling the disease severity in RA patients, as well as to evaluate whether syndecan-1 can be used as a therapeutic target to control disease activity. This evidence concerns the gene SDC1 and rheumatoid arthritis.